New-Overview

N8 Medical, LLC, a clinical-stage medical device company, is at the forefront of commercializing innovative medical devices enhanced with a novel class of active compounds known as Ceragenins.

N8 Medical’s goal is to revolutionize the safety of indwelling medical devices and implants. By applying our innovative CeraShield coating to these devices, we aim to prevent Hospital-Acquired Infections (HAIs), thereby reducing the reliance on antibiotics and combating Antimicrobial Resistance (AMR).

About Us

N8 Medical, LLC, a clinical-stage medical device company, is at the forefront of commercializing innovative medical devices enhanced with a novel class of active compounds known as Ceragenins.

N8 Medical’s goal is to revolutionize the safety of indwelling medical devices and implants. By applying our innovative CeraShield coating to these devices, we aim to prevent Hospital-Acquired Infections (HAIs), thereby reducing the reliance on antibiotics and combating Antimicrobial Resistance (AMR).

As an integral part of N8 Biosciences, a holding company committed to the extensive application of Ceragenins, N8 Biosciences is making strides in two key areas :

  1. The development of CeraShield, a specialized coating for medical devices, aimed at preventing infections.
  2. Through our subsidiary, Kinnear Pharmaceuticals (www.kinnearpharma.com), we’re advancing therapeutic research and drug development. Our focus is on creating treatments for a range of conditions, including cystic fibrosis (CF) and Kostmann’s disease, leveraging the unique properties of Ceragenins that mimic the activity of naturally occurring innate immune system compounds such as LL-37.

The Company’s proprietary technology is based on Dr. Paul B. Savage’s research and invention at Brigham Young University (BYU).

What sets our Ceragenins apart? These synthetic molecules are designed to mimic endogenous host defense peptides – nature’s own way of combating pathogens. They replicate the multifaceted activities of natural antimicrobial peptides, but with enhanced stability and manufacturability. Unlike peptides, Ceragenins resist proteolytic degradation and can be produced on a large scale, making them a practical solution for widespread use.

As an integral part of N8 Biosciences, a holding company committed to the extensive application of Ceragenins, N8 Biosciences is making strides in two key areas:

  • The development of CeraShield, a specialized coating for medical devices, aimed at preventing infections.
  • Through our subsidiary, Kinnear Pharmaceuticals (www.kinnearpharma.com), we're advancing therapeutic research and drug development. Our focus is on creating treatments for a range of conditions, including cystic fibrosis (CF) and Kostmann’s disease, leveraging the unique properties of Ceragenins that mimic the activity of naturally occurring innate immune system compounds such as LL-37.
The Company’s proprietary technology is based on Dr. Paul B. Savage’s research and invention at Brigham Young University (BYU).

Here's why Ceragenins are groundbreaking

  • They possess a unique mechanism of action, distinct from traditional treatments.
  • Their antimicrobial potency is exceptional, effectively targeting multidrug-resistant strains and biofilms.
  • They have a reduced likelihood of prompting bacterial resistance – a significant advancement in infectious disease treatment.
  • Beyond fighting infections, Ceragenins have promising anti-inflammatory properties and can synergize with conventional antibiotics.
  • Our innovative approach is secured by patent protection extending into the mid-2030s and beyond.

Here's why Ceragenins are groundbreaking

  • They possess a unique mechanism of action, distinct from traditional treatments.
  • Their antimicrobial potency is exceptional, effectively targeting multidrug-resistant strains and biofilms.
  • They have a reduced likelihood of prompting bacterial resistance – a significant advancement in infectious disease treatment.
  • Beyond fighting infections, Ceragenins have promising anti-inflammatory properties and can synergize with conventional antibiotics.
  • Our innovative approach is secured by patent protection extending into the mid-2030s and beyond.

AMR

The next pandemic is already here

Leading Infectious Disease experts have labeled the crisis of Antimicrobial Resistant (AMR) Infections as “The Silent Pandemic.” Biofilm fouling of medical devices account for approximately 65% of HAIs.One factor that is inextricably linked to, and exacerbates antibiotic resistance has been consistently overlooked to date; this factor is biofilm.In 2001, Dr. Bell, Deputy Director of CDC′s Division of Healthcare Quality Promotion, authored a seminal article “Biofilms: A Clinical Perspective” in which he said:

  • A fundamental shift is needed in our approach to patient care and infectious diseases if we are to prevent device-associated infections, treatment failures, and undesired consequences (e.g. selection for antimicrobial-resistant bacterial strains) due to biofilm-related infections.

AMR

The next pandemic is already here

Leading Infectious Disease experts have labeled the crisis of Antimicrobial Resistant (AMR) Infections as “The Silent Pandemic.”

Biofilm fouling of medical devices account for approximately 65% of HAIs.

One factor that is inextricably linked to, and exacerbates antibiotic resistance has been consistently overlooked to date; this factor is biofilm.
In 2001, Dr. Bell, Deputy Director of CDC′s Division of Healthcare Quality Promotion, authored a seminal article “Biofilms: A Clinical Perspective” in which he said:
A fundamental shift is needed in our approach to patient care and infectious diseases if we are to prevent device-associated infections, treatment failures, and undesired consequences (e.g. selection for antimicrobial-resistant bacterial strains) due to biofilm-related infections.

N8 Medical’s goal is to revolutionize the safety of indwelling medical devices and implants. By applying our innovative CeraShield coating to these devices, we aim to prevent Hospital-Acquired Infections (HAIs), thereby reducing the reliance on antibiotics and combating Antimicrobial Resistance (AMR).

N8 Medical’s goal is to revolutionize the safety of indwelling medical devices and implants. By applying our innovative CeraShield coating to these devices, we aim to prevent Hospital-Acquired Infections (HAIs), thereby reducing the reliance on antibiotics and combating Antimicrobial Resistance (AMR).

DR.I.Semmelweis

In the mid-19th century, Ignaz Semmelweis, a Hungarian physician, made a groundbreaking discovery at the Vienna General Hospital. Confronted with high mortality rates in the maternity ward, Semmelweis observed a critical difference between two wards: one staffed by doctors and medical students and the other by midwives. The former had significantly higher infection rates and fatalities among new mothers.
Semmelweis traced the root cause to the doctors and students who, unlike the midwives, conducted autopsies and then attended childbirths without washing their hands. His solution was simple yet revolutionary for the time: mandatory handwashing with a chlorine solution  for all medical staff before examining patients. This intervention drastically reduced the incidence of puerperal fever, a common and often fatal infection.
The present fight against Hospital-Acquired Infections (HAIs) and AMR echoes the challenges faced by Dr. Semmelweis. Today we have technology available to be applied as antimicrobial coating of medical devices. This approach is analogous to Semmelweis’s handwashing protocol, serving as a critical barrier against infections.
Ignaz_Semmelweis_1858

Contact us

Lets Get in Touch!

  • info@n8medical.com
  • N8 Medical LLC - 545 Metro Place, Dublin, OH, 43107
Follow now
Linkedin

mynewform

Basic contact form

Contact us

Lets Get in Touch!

  • info@n8medical.com
  • N8 Medical, LLC1090 Center DrivePark City, UT 84098
Follow now
Linkedin

mynewform

Basic contact form

N8 Medical, Inc. (N8 Medical) is a clinical-stage medical device company focused on commercializing medical devices that incorporate a novel class of active compounds called ceragenins.The subsidiaries for N8 Medical Inc are N8 Medical, LLC for Medical Device Development and Kinnear Pharmaceuticals, LLC for drug development.

Useful Links

Our Company